RGS16 and neoplasm: In summary, the impact of RGS16 on CRC development seems to be bidirectional since, on the one hand, it inhibits both prooncogenic signaling cascade depending on PAR4 and, on the other hand, limits the anti-tumor activity of the CD8+ lymphocytes; however, the impact of RGS16 on the immune system requires further studies.